Anacor Pharmaceuticals Inc Announces Positive Preliminary Results From Phase 2b Trial. Print E-mail
By Staff and Wire Reports   
Monday, 27 June 2011 19:23
Below is a look at some of the headlines for companies that made news in the healthcare sector on June 27, 2011.

Anacor Pharmaceuticals Inc., (NASDAQ:ANAC), announced preliminary results from its Phase 2b trial of AN2728 for the treatment of mild-to-moderate plaque-type psoriasis.

The trial enrolled 68 subjects randomized in a 2:1 ratio. Subjects treated with AN2728 showed improvement over vehicle at each of the recorded timepoints during the 12 week study period with peak efficacy of 26% occurring after six weeks of treatment with AN2728.

The trial was designed to provide preliminary indications of efficacy and local tolerability and systemic safety when treating all or nearly all of the plaques on each subject.

The previous four Phase 1 and three Phase 2 trials assessing the safety and efficacy of AN2728 had been designed to treat psoriasis on smaller body surface areas.

This Phase 2b trial, while not powered to demonstrate statistical significance, was conducted under anticipated Phase 3 conditions to inform the design and conduct of fully-powered Phase 3 trials.


Also Monday:


Advanced Cell Technology, Inc. (OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has officially granted ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells designation as an orphan medicinal product for the treatment of Stargardt's Macular Dystrophy (SMD).

Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare diseases, today announced that it has been added to the U.S. broad-market Russell 3000® and small-cap Russell 2000® Indexes.

APAC Customer Services, Inc. (NASDAQ: APAC)
, a leader in global outsourced services and solutions, has opened a new contact center in Montevideo, Uruguay.

Caliper Life Sciences, Inc. (NASDAQ:CALP)
today announced a collaboration with Edge BioSystems, Inc., an innovative sequencing service provider based in Gaithersburg, Md.

Chembio Diagnostics, Inc. (OTCQB: CEMI) (OTCBB: CEMI) ("Chembio" or the "Company"), which develops, manufactures, markets and licenses point-of-care diagnostic tests, has initiated studies required for submission of an Investigational Device Exemption (IDE) to the Food and Drug Administration for its Sure Check® rapid HIV Test as the first step toward over-the-counter (OTC) product approval.

Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) today provided a clarification of facts arising out of a blog post on Friday, June 24, 2011.

Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, announced that it has listed and begun trading of American Depository Receipts (ADR) through BNY Mellon.

MMRGlobal, Inc. (OTCBB: MMRF) today announced that following the impending closing of Google Health, MyMedicalRecords, the Company's consumer Personal Health Record (PHR), stands alone as the single easiest to access and use, secure, multilingual PHR with more than 700,000 members.

mPhase Technologies, Inc. (OTCBB: XDSL) today announced that it has released a new video that describes how the company has focused its technical skills on the development of smart surface materials that have the ability to selectively control the flow of liquids through a porous substrate.

Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has completed dosing the first patient in Part B of the ongoing Phase I study.

Pacira Pharmaceuticals, Inc., (Nasdaq:PCRX), an emerging specialty pharmaceutical company, today announced that it has been included in the Russell 3000® Index following Russell Investments' reconstitution of its comprehensive set of U.S. and global equity indexes on June 24, 2011.

PharmAthene, Inc. (NYSE Amex:PIP) announced today that it has achieved an important technical milestone in its recombinant protective antigen (rPA) anthrax vaccine program.  

Sanofi (EURONEXT: SAN and NYSE:SNY) announced today, at the 71st Scientific American Diabetes Association Sessions 2011, the results of three studies showing that people with diabetes using Sanofi insulins Lantus® and/or Apidra® with the insulin delivery device SoloSTAR® experienced greater treatment satisfaction, better quality of life and lower fear of hypoglycemia vs those using a premixed insulin product.

Soligenix, Inc. (OTCBB: SNGX), a late-stage biopharmaceutical company, announces the appointment of Jerome Zeldis, MD, PhD, Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation, and Keith Brownlie, CPA, former partner at Ernst & Young, LLP to its Board of Directors.

Sunshine Biopharma Inc. (OTCBB: SBFM) a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a human microsome stability study of its lead compound, Adva-27a targeted for aggressive types of cancer including multidrug resistant breast cancer.

Verenium Corporation (Nasdaq:VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, and Novus International Inc., a leading manufacturer of animal and human nutrition and health products, today announced a strategic collaboration to jointly develop and commercialize a suite of new enzyme products from Verenium's late-stage product pipeline in the animal nutrition and health area globally.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter